May 4, 2017 08:18 AM EDT
R&D
Pharma

No­var­tis con­tin­ues its blitz on NASH deals, grab­bing an ex­clu­sive tie-up in race to de­vel­op cock­tails

John Carroll

Editor & Founder

Five months ago No­var­tis $NVS rocked Cona­tus’ world with a col­lab­o­ra­tion deal for its NASH drug em­ri­c­as­an. The biotech’s stock quadru­pled in val­ue. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times